ReviewInfectious diseases & immunity2025
The regulation of innate antiviral immunity by TRIM56.
Review in Infectious diseases & immunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- TRIM56 Promotes Antiviral Responses Downstream of TLR4.Viruses · 2026Article
- ATG7 Limits Basal Antiviral Gene Expression and Moderately Promotes VSV Replication in Mammalian Non-Immune Cells.Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A member of the tripartite-motif (TRIM) protein family of E3 ligases, TRIM56 has increasingly been recognized as a versatile player in innate antiviral immunity that operates via catalytically-dependent and catalytically-independent mechanisms. Herein, we provide a concise overview of the various roles that TRIM56 has been demonstrated to play in host interactions with viruses, including its "direct" virus-restricting activities and "indirect" antiviral effects resulting from its positive regulation of innate immune signaling. In addition, we discuss the current understanding of the molecular determinants and underlying biology by which TRIM56 functions in these processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.